Please ensure Javascript is enabled for purposes of website accessibility

4 Reasons Philip Morris International Shouldn't Merge With Altria

By Leo Sun – Updated Aug 28, 2019 at 9:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

PMI shouldn’t agree to bail out Altria’s ailing domestic business.

Eleven years ago, tobacco giant Altria (MO 1.66%) finished spinning off its international business as Philip Morris International (PM 1.92%). The split let Altria focus on tackling litigation and declining sales in America, and allowed PMI to expand more aggressively in overseas markets with higher smoking rates.

But smoking rates fell worldwide over the past decade, forcing both companies to repeatedly raise prices and cut costs to stay profitable. Regulators exacerbated the pain by tightening regulations on tobacco and e-cigarettes.

A woman refuses a cigarette.

Image source: Getty Images.

To make matters worse, British American Tobacco (BTI 2.25%) overtook PMI as the world's largest publicly traded tobacco company in 2017 by acquiring Altria's rival Reynolds American. In response, many analysts suggested that Altria and PMI, which were already partnered in the development of alternative smoking products, should reunite to stay competitive.

Altria and PMI apparently listened to those suggestions, and the companies recently confirmed that they were mulling an all-stock "merger of equals," in which investors in both companies trade their shares for shares of a new company. That might sound like a reasonable proposition, but it's a terrible idea, for four simple reasons.

1. PMI has better growth than Altria

PMI sells its products across six geographical regions: the European Union, Eastern Europe, Middle East & Africa, South & Southeast Asia, East Asia & Australia, and Latin America & Canada.

Last quarter PMI's sales across all of those regions except Latin America & Canada rose on a constant currency basis as it offset its lower shipments with price hikes and sales of iQOS heated tobacco products. PMI's total cigarette shipments fell 3.6% annually, but shipments of its heated tobacco products surged 37%, causing its total (cigarette and heated tobacco) shipments to dip just 0.1% on a like-for-like basis. As a result, PMI's revenue rose 9% on a constant currency like-for-like basis during the quarter.

Altria's cigarette shipments, excluding trade inventory movements, fell 7% annually last quarter. Its shipments of smokeless (mainly snuff and snus) products also fell 3% on the same basis. Altria's revenue still rose 6% annually thanks to price hikes, but it's growing at a slower pace than PMI.

Merging Altria's U.S. operations back into PMI would increase the latter's annual revenue net of excise taxes by roughly two-thirds -- but the addition of that slower-growth revenue would offset the stronger growth of PMI's other regions.

2. PMI has higher gross margins than Altria

PMI has also consistently generated higher gross margins than Altria since the split:

PM Gross Profit Margin (TTM) Chart

PM Gross Profit Margin (TTM) data by YCharts

PMI has higher margins because it has lower manufacturing costs and better pricing power than Altria in many markets. Blending Altria's lower-margin revenue with PMI's isn't in the best interest of the latter's shareholders.

Altria might argue that the combination would generate synergies by merging sales and R&D teams for heated tobacco products -- but Altria and PMI already pooled those resources several years ago.

3. Altria has rising debt, PMI has declining debt

Altria's long-term debt surged from $11.9 billion at the end of 2018 to $27.1 billion at the end of the second quarter. That increase can be attributed to two recent investments: a $12.8 billion stake in e-cigarette maker Juul, and a $1.8 billion stake in Canadian cannabinoid company Cronos.

Neither of those businesses is an established growth engine like iQOS. Altria's massive investment in Juul is questionable, since the company only generates about $1.5 billion in annual revenue and is being pilloried by the FDA. Its investment in Cronos is also highly speculative, since it only generated $15.7 million in revenue last year.

Meanwhile, PMI reduced its long-term debt from $27 billion to $24.9 billion during the same period. Unlike Altria, which constantly uses its free cash flow to repurchase shares and boost its EPS, PMI hasn't repurchased any shares in recent quarters due to currency headwinds. Instead, it allocates more of its cash toward extinguishing its debt. Therefore, merging the two companies punishes PMI shareholders for Altria's speculative bets.

A woman breaks a cigarette in half.

Image source: Getty Images.

4. A divided board and management

PMI and Altria will have to figure out how to bring together their respective boards of directors and management teams to lead the combined company. At present, the way the two companies have handled key issues in the past could cause friction and affect decisions about buybacks, dividends, and new products like e-cigarettes, heated tobacco products, and marijuana.

In fact, PMI CEO Andre Calantzopoulos previously criticized Juul for causing a teen vaping "epidemic" in the U.S., and stated that he wasn't interested in investing in cannabis products -- which casts a cloud over Altria's recent investments.

PMI and Altria both have a lot of moving parts, and merging them together again would likely throttle the efficiency of both sides instead of generating meaningful synergies.

PMI investors should reject this idea

Altria seems to want PMI to bail out its ailing domestic business with a merger. That might benefit Altria's investors, but it would hurt PMI investors. PMI still has potential catalysts on the horizon -- including a weaker dollar and the growth of iQOS -- but those tailwinds will fade away if it merges with Altria.

Leo Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altria Group Stock Quote
Altria Group
$46.58 (1.66%) $0.76
Philip Morris International Stock Quote
Philip Morris International
$99.67 (1.92%) $1.88
British American Tobacco Stock Quote
British American Tobacco
$41.27 (2.25%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.